Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

Overview of attention for article published in Advances in Therapy, January 2010

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)

Mentioned by

policy: 1 policy source

patent: 1 patent

Citations

dimensions_citation: 168 Dimensions

Readers on

mendeley: 198 Mendeley

Summary Policy documents Patents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis : Committee papers

Cited by National Institute for Health and Care Excellence on 15 Jan 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Daclizumab for treating relapsing–remitting multiple sclerosis: Committee papers

Cited by National Institute for Health and Care Excellence on 23 Sep 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.